Calithera Biosciences Reports First Quarter 2017 Financial Results and Recent Highlights
May 09, 2017 20:13 pm UTC| Business
-Strong quarter-end cash position of $207.1 million supports advancement of multiple clinical development programs-Calithera to Host Conference Call Today at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time SOUTH SAN...
GW Pharmaceuticals plc Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress
May 09, 2017 20:13 pm UTC| Business
- Epidiolex® NDA submission expected mid-year -- New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology -- Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 -- GW Pharmaceuticals...
GW Pharmaceuticals plc Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress
May 09, 2017 20:13 pm UTC| Business
- Epidiolex® NDA submission expected mid-year -- New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology -- Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 -- GW Pharmaceuticals...
Calithera Biosciences Reports First Quarter 2017 Financial Results and Recent Highlights
May 09, 2017 20:13 pm UTC| Business
-Strong quarter-end cash position of $207.1 million supports advancement of multiple clinical development programs-Calithera to Host Conference Call Today at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time SOUTH SAN...
GW Pharmaceuticals plc Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress
May 09, 2017 20:13 pm UTC| Business
- Epidiolex® NDA submission expected mid-year -- New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology -- Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 -- GW Pharmaceuticals...
GW Pharmaceuticals plc Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress
May 09, 2017 20:13 pm UTC| Business
- Epidiolex® NDA submission expected mid-year -- New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology -- Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 -- GW Pharmaceuticals...
GW Pharmaceuticals plc Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress
May 09, 2017 20:13 pm UTC| Business
- Epidiolex® NDA submission expected mid-year -- New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology -- Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 -- GW Pharmaceuticals...